In addition, Gaedicke and colleagues have developed the antibody-based agent (64Cu-NOTA-AC133) for CD133+CSCs detection in subcutaneous and orthotopic glioma xenografts [61]. This evidence concerns the gene PROM1 and central nervous system cancer.